RenovoRx (RNXT)
NASDAQ:RNXT
Want to see RNXT full AI Analyst Report?
Earnings Data
Report Date
Aug 13, 2026After Close (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-0.07Last Year’s EPS
-0.08Same Quarter Last Year
Strong Buy
Based on 4 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call presented strong commercial momentum and meaningful operational milestones: record quarterly revenue with very high gross margins, rapid expansion of active centers and a sizable prospect pipeline, near-completion of the pivotal Phase III trial, and a successful $10M private placement providing runway into H2 2027. Offsetting factors include still-modest absolute revenue, sizable operating expenses (R&D $1.2M; SG&A ~$2.7M), remaining trial and event targets to achieve, and timing/convertibility risk of pipeline centers. Overall the positive execution on commercial scaling, healthy margins, and a reinforced balance sheet materially outweigh the near-term risks described.Company Guidance
Record Quarterly Revenue and Rapid Growth
Q1 2026 revenue of $563,000 was the company's highest quarterly revenue to date, representing ~136% quarter-over-quarter growth vs Q4 2025 ($238,000) and ~186% year-over-year growth vs Q1 2025 ($197,000). Q1 2026 revenue accounts for approximately 51% of total 2025 revenue ($1.1M).
Very High Gross Margin
Gross profit for Q1 2026 was $479,000, corresponding to a gross margin of 85.1%, indicating attractive unit economics for the RenovoCath device.
Commercial Footprint Expansion
Active commercial cancer centers increased to 16 as of May 2026 (up from 5 at the start of 2025 and 8 at year-end 2025). There are 32 additional centers in evaluation/approval/activation for a total pipeline of 48 centers — described as a quadrupling vs Q1 2025. Management targets 36 active centers by year-end 2026.
Repeat Orders and Physician Adoption
Management reports strong repeat order behavior and physician-to-physician advocacy as adoption drivers; RenovoCath has been used in >750 procedures since initial 510(k) clearance in 2014, supporting durability of commercial traction.
Phase III TIGeR-PaC Trial Nearing Enrollment Completion
As of May 14, 2026, TIGeR-PaC had randomized 106 of 114 required patients (~93%) with 74 of 86 required events observed (~86%). Management expects enrollment closure by end of June 2026 and final data in mid-to-late 2027, which supports site conversions to commercial use.
Successful Financing and Cash Runway
Closed an oversubscribed private placement in March 2026 generating approximately $10.0M in gross proceeds. Cash and cash equivalents were ~$12.4M as of March 31, 2026, providing runway into the second half of 2027 per management.
Reiterated 2026 Revenue Guidance and Q2 Outlook
Management reiterated full-year 2026 revenue guidance of $3.0M–$4.0M and expects Q2 2026 revenue to exceed Q1 2026, driven by expanding active centers and anticipated conversions of Phase III sites.
Scientific Validation and New Investigator-Initiated Trials
A TIGeR-PaC pharmacokinetic sub-study was presented at ASCO-GI showing reduced systemic gemcitabine levels with TAMP/IAG vs IV gemcitabine; the full paper is submitted. Two new IITs (metastatic and borderline resectable pancreatic cancer) have been greenlighted, expanding clinical interest and potential indications.
RNXT Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
RNXT Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 14, 2026 | $0.85 | $0.82 | -4.09% |
Apr 01, 2026 | $0.97 | $0.98 | +1.03% |
Nov 13, 2025 | $0.97 | $0.75 | -23.00% |
Aug 14, 2025 | $1.24 | $0.95 | -22.98% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does RenovoRx (RNXT) report earnings?
RenovoRx (RNXT) is schdueled to report earning on Aug 13, 2026, After Close (Confirmed).
What is RenovoRx (RNXT) earnings time?
RenovoRx (RNXT) earnings time is at Aug 13, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is RNXT EPS forecast?
RNXT EPS forecast for the fiscal quarter 2026 (Q2) is -0.07.